Paper · 24048522

Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.

Garcia S and 11 others. Sci Transl Med, 2013. Cited by 75 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Papers, record 24048522. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24048522

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.; PubMed
Journal: Sci Transl Med; PubMed
Year: 2013; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/24048522/; PubMed
DOI: https://doi.org/10.1126/scitranslmed.3006247; PubMed
The journal: https://conductscience.org/library/journal-index/101505086; PubMed
Citations, by iCite: 75; iCite
Relative citation ratio, by iCite: 2.25; iCite
Revised in PubMed: 2013-09-19; PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Garcia S	Stéphanie
2	Dirat B	Béatrice
3	Tognacci T	Thomas
4	Rochet N	Nathalie
5	Mouska X	Xavier
6	Bonnafous S	Stéphanie
7	Patouraux S	Stéphanie
8	Tran A	Albert
9	Gual P	Philippe
10	Le Marchand-Brustel Y	Yannick

1 to 10 of 12Source PubMed

See all 12 authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Achondroplasia	Major topic
Bone Development	Major topic
Receptor, Fibroblast Growth Factor, Type 3	Major topic
Animals
Female
Humans
Male
Mice
Signal Transduction

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by51

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 75 citations.

PMID	Title	Journal	Year	In Papers	Source
42,883,818	Achondroplasia: Current Disease-Modifying Therapies and Genome Editing Strategies.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42883818	PubMed
40,256,430	Advances in the mechanism and therapies of achondroplasia.	Genes Dis	2025	https://conductscience.org/library/papers/40256430	PubMed
40,178,985	TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia.	JCI Insight	2025	https://conductscience.org/library/papers/40178985	PubMed
39,473,750	Predictive value of preoperative Fried Frailty Phenotype assessment and serum biomarkers on the prognosis of elderly patients with femoral neck fracture under general anesthesia within 3 months after surgery.	Turk J Med Sci	2024	https://conductscience.org/library/papers/39473750	PubMed
38,544,920	Long-term oral meclozine administration improves survival rate and spinal canal stenosis during postnatal growth in a mouse model of achondroplasia in both sexes.	JBMR Plus	2024	https://conductscience.org/library/papers/38544920	PubMed
38,455,469	Tumour cell-expressed PD-L1 reprograms lipid metabolism via EGFR/ITGB4/SREBP1c signalling in liver cancer.	JHEP Rep	2024	https://conductscience.org/library/papers/38455469	PubMed
38,045,829	Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy.	MedComm (2020)	2023	https://conductscience.org/library/papers/38045829	PubMed
37,428,729	Phase 1b study on the repurposing of meclizine hydrochloride for children with achondroplasia.	PLoS One	2023	https://conductscience.org/library/papers/37428729	PubMed
36,765,071	Intrafusal-fiber LRP4 for muscle spindle formation and maintenance in adult and aged animals.	Nat Commun	2023	https://conductscience.org/library/papers/36765071	PubMed
36,684,552	Achondroplasia: Clinical, Radiological and Molecular Profile from Rare Disease Centre, India.	J Pediatr Genet	2023	https://conductscience.org/library/papers/36684552	PubMed

1 to 10 of 51

See all 51 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
FGFR3	2,261	PubTator's text mining	https://conductscience.org/library/genes/2261

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24048522

GET https://conductscience.org/api/papers/v1/24048522/cited_by?page=2

API reference For AI assistants